万邦医药(301520.SZ)：预计2025年净利润同比下降50.70%-66.55%

Core Viewpoint - Wanbang Pharmaceutical (301520.SZ) expects a significant decline in net profit attributable to shareholders for 2025, forecasting a range of 28.61 million to 42.16 million yuan, representing a decrease of 50.70% to 66.55% compared to the previous year [1] Group 1: Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between 7.45 million and 10.97 million yuan, reflecting a substantial decline of 80.33% to 86.65% year-on-year [1] - The company's revenue and gross margin from its generic drug business have experienced a decline due to intensified competition in the industry and fluctuations in customer demand [1]